EQ
Equillium, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.43
+1.06%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.49
From 52W high−55.47%
Volume38356.00
Market cap$111.67M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.49
From 52W high
−55.47%
Volume
38356.00
Market cap
$111.67M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
P/E (TTM)
—
RSI (14)
46.1
MomentumView details →
1D Return
+1.06%
YTD Return
−9.35%
SummaryUpdated Jun 1, 2026
Equillium, Inc. (NASDAQ:EQ) is a clinical-stage biotechnology company founded in 2017 and headquartered in La Jolla, California. The company was originally incorporated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium in May 2017. Equillium went public in October 2018 and focuses on developing treatments for severe autoimmune and inflammatory disorders that currently have limited treatment options. The company is primarily engaged in advancing its lead drug candidate through clinical trials while also developing a pipeline of additional therapeutic candidates.
Similar companies
Latest newsMore news →
Equillium dosed the first subject in Australia in its Phase 1 clinical trial of EQ504.9d agoEquillium, Inc. announced a poster presentation of new preclinical data on EQ504 at the 50th Anniversary Equillium, Inc..29d agoEquillium received Australian regulatory clearance to initiate a first-in-human clinical trial of EQ504, with dosing planned to begin by early November 2026.30d ago